首页 | 本学科首页   官方微博 | 高级检索  
     


No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide,thalidomide, and bortezomib in patients with Multiple Myeloma
Authors:Annette J Vangsted  Karen Søeby  Tobias W Klausen  Niels Abildgaard  Niels F Andersen  Peter Gimsing  Henrik Gregersen  Ulla Vogel  Thomas Werge  Henrik B Rasmussen
Affiliation:(1) Dept. of Oncology and Haematology, Roskilde Hospital, Copenhagen University, Roskilde, DK, 4000, Denmark;(2) Dept. of Clinical Biochemistry, Hvidovre University Hospital, 2650 Hvidovre, Denmark;(3) Dept. of Haematology, University Hospital of Copenhagen at Herlev, Herlev, DK, 2730, Denmark;(4) Dept. of Haematology, Odense University Hospital, Odense, DK, 5000, Denmark;(5) Dept. of Haematology, Aarhus University Hospital, Aarhus, DK, 8000, Denmark;(6) Dept. of Haematology, University Hospital of Copenhagen at Rigshospitalet, Copenhagen, DK, 2100, Denmark;(7) Dept. of Haematology, Aalborg University Hospital, Aalborg, DK, 9100, Denmark;(8) National Food Institute, Technical University of Denmark, DK, 2860 Copenhagen, Denmark;(9) Institute for Science, Systems and Models, Roskilde University, Roskilde, DK, 4000, Denmark;(10) National Research Centre for the Working Environment, DK, 2100 Copenhagen, Denmark;(11) Research Institute of Biological Psychiatry, Mental Health Center Sct. Hans, University Hospital of Copenhagen, Roskilde, DK, 4000, Denmark
Abstract:

Background  

The response to treatment varies among patients with multiple myeloma and markers for prediction of treatment outcome are highly needed. Bioactivation of cyclophosphamide and thalidomide, and biodegradation of bortezomib, is dependent on cytochrome P450 metabolism. We explored the potential influence of different polymorphisms in the CYP enzymes on the outcome of treatment.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号